Research ArticleSpecial Section on Transporters in Toxicity and Disease
6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects
Yuichiro Imamura, Yuri Tsuruya, Katja Damme, Dominik Heer, Yuji Kumagai, Kazuya Maeda, Nobuyuki Murayama, Noriko Okudaira, Atsushi Kurihara, Takashi Izumi, Yuichi Sugiyama and Hiroyuki Kusuhara
Drug Metabolism and Disposition April 2014, 42 (4) 685-694; DOI: https://doi.org/10.1124/dmd.113.055475
Yuichiro Imamura
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Yuri Tsuruya
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Katja Damme
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Dominik Heer
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Yuji Kumagai
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Kazuya Maeda
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Nobuyuki Murayama
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Noriko Okudaira
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Atsushi Kurihara
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Takashi Izumi
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Yuichi Sugiyama
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Hiroyuki Kusuhara
Drug Metabolism & Pharmacokinetics Research Laboratories, R&D Division, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan (Y.I., N.M., N.O., A.K., T.I.); Daiichi Sankyo Tissue and Cell Research Center Munich, Daiichi Sankyo Europe GmbH, Martinsried, Germany (K.D., D.H.); Clinical Trial Center, Kitasato East Hospital, Sagamihara, Kanagawa, Japan (Y.K.); Sugiyama Laboratory, RIKEN Innovation Center, Research Cluster for Innovation, RIKEN, Yokohama, Kanagawa, Japan (Y.S.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan (Y.T., K.M., H.K.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleSpecial Section on Transporters in Toxicity and Disease
6β-Hydroxycortisol as Endogenous In Vivo Probe for OAT3
Yuichiro Imamura, Yuri Tsuruya, Katja Damme, Dominik Heer, Yuji Kumagai, Kazuya Maeda, Nobuyuki Murayama, Noriko Okudaira, Atsushi Kurihara, Takashi Izumi, Yuichi Sugiyama and Hiroyuki Kusuhara
Drug Metabolism and Disposition April 1, 2014, 42 (4) 685-694; DOI: https://doi.org/10.1124/dmd.113.055475
Research ArticleSpecial Section on Transporters in Toxicity and Disease
6β-Hydroxycortisol as Endogenous In Vivo Probe for OAT3
Yuichiro Imamura, Yuri Tsuruya, Katja Damme, Dominik Heer, Yuji Kumagai, Kazuya Maeda, Nobuyuki Murayama, Noriko Okudaira, Atsushi Kurihara, Takashi Izumi, Yuichi Sugiyama and Hiroyuki Kusuhara
Drug Metabolism and Disposition April 1, 2014, 42 (4) 685-694; DOI: https://doi.org/10.1124/dmd.113.055475
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement